UK US CA
Visiting from the United States? GLPInfo has a North American edition with US channels and dollar prices: open the US edition. Canada follows in a later release.
Research → decisions → accessEvidence checked 13 Sep 2026

Follow the science.
See what comes next.

A clearer view of the milestones shaping peptide and GLP-1 medicines in the UK, US and EU: confirmed decisions, company targets and clearly labelled estimates, each with its source. What we track · How estimates are made.

Liraglutide

Novo Nordisk · GLP-1 receptor agonist · Peptide
RangeNext four yearsAll milestonesZoomQuartersYears
Region
201020112012201320142015201620172018201920202021202220232024202520262027202820292030
USFDA
Today25 Jan 2010 · approval23 Dec 2014 · approval
UKMHRA
No verified events yet
EUEMA / European Commission
No verified events yet
US · 25 Jan 2010 · approvalConfirmed · 25 Jan 2010US · 23 Dec 2014 · approvalConfirmed · 23 Dec 2014
Confirmed eventCompany targetRegulator targetEditorial estimateTiming unknown or undatedSafety update

Dashed line: today, 13 Sep 2026. Future windows are conditional. Approval, launch and funded access are separate milestones.

Confirmed · 23 Dec 2014United States

FDA approves Saxenda (liraglutide 3 mg) for chronic weight management

Original approval of NDA 206321 on 23 December 2014 for chronic weight management in adults.

Why it matters. The first GLP-1 medicine licensed for weight management; it set the template later followed by Wegovy and Zepbound.

Event
Approval
Indication
Chronic weight management (Obesity, or overweight with at least one weight-related condition, alongside diet and physical activity)
Product
Saxenda, once-daily injection
Authority
FDA
Event date
23 Dec 2014
Published
13 Sep 2026
Last checked
13 Sep 2026
Record version
v1
US Food and Drug Administration (Drugs@FDA) ↗ Report a correction Follow Liraglutide Confirmed
Select a milestone to see its evidence. Keyboard: Tab to a marker, arrow keys to move, Enter to open.Estimates describe timing only, never a probability of approval.

All Liraglutide records (accessible list)

Liraglutide

Once-daily GLP-1 receptor agonist; the first GLP-1 medicine licensed for weight management.

United Kingdom

No verified events recorded yet. Regulator: MHRA.

United States

· Approval Confirmed

FDA approves Victoza (liraglutide) for type 2 diabetes

Victoza (once-daily injection) · Type 2 diabetes (glycaemic control)

Original approval of NDA 022341 on 25 January 2010 for glycaemic control in adults with type 2 diabetes.

Why it matters: The earliest approval in this tracker; liraglutide's core patents have since expired, which matters for generic availability rather than for its approval status.

Source: US Food and Drug Administration (Drugs@FDA)

Last checked 13 Sep 2026 · Report a correction

· Approval Confirmed

FDA approves Saxenda (liraglutide 3 mg) for chronic weight management

Saxenda (once-daily injection) · Chronic weight management

Original approval of NDA 206321 on 23 December 2014 for chronic weight management in adults.

Why it matters: The first GLP-1 medicine licensed for weight management; it set the template later followed by Wegovy and Zepbound.

Source: US Food and Drug Administration (Drugs@FDA)

Last checked 13 Sep 2026 · Report a correction

European Union

No verified events recorded yet. Regulator: EMA / European Commission.

This list is the complete, accessible view of the tracker; the board above draws from exactly the same records. Every entry is labelled Confirmed (official record), Company target (a dated sponsor statement), Regulator target (an official decision date, not a guarantee), GLPInfo estimate (an editorial range with assumptions) or Timing unknown. An approval is never inferred from a target date passing.